Skip to content

US · 21 CFR

21 CFR 610.42

Restrictions on use for further manufacture of medical devices.

21 CFR Part 610 › Subpart E—Testing Requirements for Relevant Transfusion-Transmitted Infections

Section text

(a) In addition to labeling requirements in subchapter H of this chapter, when a medical device contains human blood or a blood component as a component of the final device, and the human blood or blood component was found to be reactive by a screening test performed under § 610.40(a) and (b), then you must include in the device labeling a statement of warning indicating that the product was manufactured from a donation found to be reactive by a screening test for evidence of infection due to the identified relevant transfusion-transmitted infection(s).

(b) FDA may approve an exception or alternative to the statement of warning required in paragraph (a) of this section based on evidence that the reactivity of the human blood or blood component in the medical device presents no significant health risk through use of the medical device.

Footnotes and source notes

  • [66 FR 31164, June 11, 2001, as amended at 80 FR 29897, May 22, 2015]

Source: U.S. Office of the Federal Register / GPO — eCFR · U.S. federal government work — public domain (17 U.S.C. §105). eCFR is an editorial compilation, not an official legal edition of the CFR. · retrieved 2026-11-16

Weekly Newsletter

Get the week's FDA, EU and MFDS inspection findings

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Confirm by email to start · Unsubscribe any time